Oxolife SL 

Small-size clinical-stage company developing a firts in class treatment for female infertility.


Agnès Arbat (See Profile)




Development, market readiness, clinical trial



Oxo-001 enhances female fertility trough increasing embryo implantation and lowering postimplant losses.

Two indications: implantation enhancement and restoring ovulation in PCOS patients

76 million women diagnosed each year, despite all treatments, still 50% pregnancy failures. 5% growing market

Clinical stage developement, 3.5 years to finish Phase II clinical trials

Peak sales up to 150-260M€. 3- family member patent protection worldwide.

This information is confidential, do not share or copy.

Under evaluation at least till: 15th November

If you want to have more information or you want to review the project, you have to login or register


©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

Aviso de cookies

Log in with your credentials


Forgot your details?

Create Account

Skip to toolbar